Skip to main content
SpringerLink
Log in

The Almost Forgotten Biological Potentials of Cholesterol and its Intermediates: Cholesterol Reduction and Myositis

  • Editorial Introduction
  • Published:
Cardiovascular Drugs and Therapy Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Ballantyne CM. Current and future aims of lipid-lowering therapy: Changing paradigms and lessons from the Heart Protection Study on standards of efficacy and safety. Am J Cardiol 2003; 92: 3K-9K.

    Google Scholar 

  2. Durrington P. Dyslipidaemia. Lancet 2003; 362: 717-731.

    Google Scholar 

  3. Kastelein JJ. The future of lipid-lowering therapy: The big picture. Neth J Med 2003; 61(Suppl): 35-39.

    Google Scholar 

  4. Evans M, Rees A. Effects of HMG-CoA reductase inhibitors on skeletal muscle: Are all statins the same? Drug Saf 2002; 25: 649-663.

    Google Scholar 

  5. Mason RP, Jacob RF. Membrane microdomains and vascular biology: Emerging role in atherogenesis. Circulation 2003; 107: 2270-2273.

    Google Scholar 

  6. Kurzchalia TV, Ward S. Why do worms need cholesterol? Nat Cell Biol 2003; 5: 684-688.

    Google Scholar 

  7. Thompson PD, Clarkson P, Karas RH. Statin-associated myopathy. JAMA 2003; 289: 1681-1690.

    Google Scholar 

  8. Evans M, Rees A. The myotoxicity of statins. Curr Opin Lipidol 2002; 13: 415-420.

    Google Scholar 

  9. The statin drugs: New proof, more hope, and a disappointment. Harv Mens Health Watch 2003; 7: 5-7.

    Google Scholar 

  10. Li HY, Appelbaum FR, Willman CL, Zager RA, Banker DE. Cholesterol modulating agents kill acute meyloid leukemia cells and sensitize them to therapeutics by blocking adaptive cholesterol responses. Blood 2003; 101: 3628-3634.

    Google Scholar 

  11. Zager R. plasma membrane cholesterol: A critical determinant of cellular energetics and tubular resistance to attack. Kidney Int 2000; 58: 193-205.

    Google Scholar 

  12. Pike LJ, Casey L. Cholesterol levels modulate EGF receptor-mediated signaling by altering receptor function and trafficking. Biochemistry 2002; 41: 10315-10322.

    Google Scholar 

  13. Ushio-Fukai M, Hilenski L, Santanam N, et al. Cholesterol depletion inhibits epidermal growth factor receptor transactivation by angiotensin II in vascular smooth muscle cells: Role of cholesterol-rich microdomains and focal adhesions in angiotensin II signaling. J Biol Chem 2001; 276: 48269-48275.

    Google Scholar 

  14. Pfrieger FW. Role of cholesterol in synapse formation and function. Biochim Biophys Acta 2003; 1610: 271-280.

    Google Scholar 

  15. Silvius JR. Role of cholesterol in lipid raft formation: Lessons from lipid model systems. Biochim Biophys Acta 2003; 1610: 174-183.

    Google Scholar 

  16. Phillips PS, Haas RH, Bannykh S, et al. Statin-associated myopathy with normal creatine kinase levels. Ann Intern Med 2002; 137: 581-585.

    Google Scholar 

  17. Cauley JA, Zmuda JM, Lui LY, et al. Lipid-lowering drug use and breast cancer in older women: A prospective study. J Womens Health (Larchmt) 2003; 12: 749-756.

    Google Scholar 

  18. Beck P, Wysowski DK, Downey W, Butler-Jones D. Statin use and the risk of breast cancer. J Clin Epidemiol 2003; 56: 280-285.

    Google Scholar 

  19. Opitz JM, Gilbert-Barness E, Ackerman J, Lowichik A. Cholesterol and development: The RSH (“Smith-Lemli-Opitz”) syndrome and related conditions. Pediatr Pathol Mol Med 2002; 21: 153-181.

    Google Scholar 

  20. Li HY, Appelbaum FR, Willman CL, Zager RA, Banker DE. Cholesterol-modulating agents kill acute myeloid leukemia cells and sensitize them to therapeutics by blocking adaptive cholesterol responses. Blood 2003; 101: 3628-3634.

    Google Scholar 

  21. Xia Z, Tan MM, Wong WW, Dimitroulakos J, Minden MD, Penn LZ. Blocking protein geranylgeranylation is essential for lovastatin-induced apoptosis of human acute myeloid leukemia cells. Leukemia 2001; 15: 1398-1407.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Internal Medicine, Lung Heart Centre, University Medical Centre Utrecht, Utrecht, The Netherlands

    Marcel Twickler

  2. Department of Internal Medicine, Lung Heart Centre, University Medical Centre Utrecht, Utrecht, The Netherlands

    Jan Dirk Banga

  3. Department of Cardiology, Lung Heart Centre, University Medical Centre Utrecht, Utrecht, The Netherlands

    Maarten-Jan Cramer

Authors
  1. Marcel Twickler
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jan Dirk Banga
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Maarten-Jan Cramer
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Twickler, M., Banga, J.D. & Cramer, MJ. The Almost Forgotten Biological Potentials of Cholesterol and its Intermediates: Cholesterol Reduction and Myositis. Cardiovasc Drugs Ther 17, 395–396 (2003). https://doi.org/10.1023/B:CARD.0000015949.31908.05

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/B:CARD.0000015949.31908.05

Search

Navigation